Press Release: European Medicines Agency recommends approval of first radiopharmaceutical for PET imaging of ß-amyloid neuritic plaque density

Author (Corporate)
Series Title
Series Details EMA/CHMP/670812/2012 (19.10.12)
Publication Date 19/10/2012
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in October 2012, recommended marketing authorisation for Amyvid (florbetapir 18F) as a diagnostic agent in patients who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
Source Link Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001639.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/670812/2012 (19.10.12) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/10/WC500134106.pdf
Subject Categories
Countries / Regions